- Trial Phase
- Approved
- Time to Market
- Already approved and commercially marketed since February 2020
- Why 3/10
- NEXLETOL is already FDA-approved and commercially marketed (first approval Feb 2020, expanded CV label March 2024). There is no pending PDUFA date or pivotal-trial readout for this drug in the next ~12 months. The stock's next hard catalyst is the ARCHIMED acquisition close (expected Q3 2026 at $3.16/share), but M&A is not a drug-specific binary per impact-score rules. Hence score 3, approved product with no imminent regulatory catalyst.
NEXLETOL is already approved and generating ~$160M in annual U.S. net product sales. But ESPR stock is now primarily an M&A arbitrage play: the company agreed to a $3.16/share cash buyout by ARCHIMED (expected close Q3 2026). With the stock trading at ~$3.18, the near-term upside is capped at the deal price plus potential CVR payments; the risk is deal delay or collapse. The drug itself has no pending binary catalyst, the commercial story is about guideline adoption and formulary access, not a regulatory event.
Price Chart
Executive Summary
NEXLETOL (bempedoic acid) is a first-in-class, FDA-approved, once-daily oral non-statin cholesterol drug developed by Esperion Therapeutics (NASDAQ: ESPR). First approved in Feb 2020 for LDL-C lowering, its label was significantly expanded in March 2024 to include cardiovascular risk reduction (heart attack, revascularization) based on the CLEAR Outcomes Phase 3 trial. U.S. net product sales reached ~$159.6M in FY2025 (+38% YoY). Patent settlements push generic competition out to 2040. However, analyst consensus is heavily bearish (0 Buy, 8 Hold, 1 Sell, 2 Strong Sell), and the real story for ESPR stock now is the pending $1.1B take-private acquisition by ARCHIMED at $3.16/share (expected close Q3 2026), which caps upside. There is no pending regulatory binary for the drug itself.
How It Works
NEXLETOL is a once-daily pill that lowers "bad" LDL cholesterol by blocking an enzyme called ATP citrate lyase (ACL) in the liver, think of it as turning down the liver's cholesterol factory. Unlike statins (which target a different enzyme further down the same production line), NEXLETOL rarely causes the muscle pain that leads many patients to quit statins. It's often prescribed for patients who cannot tolerate statins or need extra cholesterol lowering on top of a statin.
Trial Status
NEXLETOL was approved by the FDA in February 2020 based on Phase 3 LDL-C lowering trials (CLEAR Harmony, CLEAR Wisdom). A landmark Phase 3 outcomes trial (CLEAR Outcomes) read out in 2023 showing a 13% relative risk reduction in MACE-4, leading to a broad FDA label expansion in March 2024 for cardiovascular risk reduction in both primary and secondary prevention patients. Post-hoc analyses continue to be presented at medical meetings (AHA 2025, ACC 2026). A Phase 3 pediatric program has been agreed with the FDA and is in initiation stages.
The Two-Sided Case
Upcoming Catalysts
- ARCHIMED acquisition closing (expected Q3 2026), the stock's primary near-term event, with shareholders receiving $3.16/share cash.
- NEXLIZET Health Canada approval decision expected in 2026 (HLS Therapeutics partner).
- Phase 3 pediatric bempedoic acid program initiation, topline data likely >2 years away.
- Quarterly earnings reports tracking commercial revenue growth trajectory and pathway to profitability.
- Continued data presentations from CLEAR Outcomes post-hoc analyses at cardiology conferences.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Esperion Therapeutics, Inc. 8-K ESPR ·Originating report